Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P, Amintas S, Caumont C, Veillon R, Galland-Girodet S, Cuguillière A, Nguyen L, Domblides C, Gouverneur A, Merlio JP, Bezin J, Girodet PO. Rosellini P, et al. Among authors: domblides c. Eur J Cancer. 2022 Sep;172:85-95. doi: 10.1016/j.ejca.2022.05.026. Epub 2022 Jun 24. Eur J Cancer. 2022. PMID: 35759814
Targeted therapy and elderly people: A review.
Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P. Daste A, et al. Among authors: domblides c. Eur J Cancer. 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Epub 2016 Nov 15. Eur J Cancer. 2016. PMID: 27855351 Review.
Immune checkpoint inhibitors and elderly people: A review.
Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A. Daste A, et al. Among authors: domblides c. Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Eur J Cancer. 2017. PMID: 28689093 Review.
Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital.
Heraudet L, Domblides C, Daste A, Gross-Goupil M, Ravaud A. Heraudet L, et al. Among authors: domblides c. Eur J Cancer. 2020 Aug;135:98-100. doi: 10.1016/j.ejca.2020.04.039. Epub 2020 Jun 17. Eur J Cancer. 2020. PMID: 32559628 Free PMC article. No abstract available.
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M, Domblides C, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Ricordel C, Fraisse P, Janicot H, Audigier-Valette C, Amour E, Langlais A, Rabbe N, Makinson A, Cadranel J, Laurent-Puig P, Lavolé A, Blons H. Wislez M, et al. Among authors: domblides c. Lung Cancer. 2021 Jul;157:124-130. doi: 10.1016/j.lungcan.2021.05.013. Epub 2021 May 13. Lung Cancer. 2021. PMID: 34016488 Clinical Trial.
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T; FHU ACRONIM. Kostine M, et al. Among authors: domblides c. Eur J Cancer. 2021 Nov;157:474-484. doi: 10.1016/j.ejca.2021.08.036. Epub 2021 Oct 11. Eur J Cancer. 2021. PMID: 34649118 Free article.
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B. Mazieres J, et al. Among authors: domblides c. J Clin Oncol. 2022 Mar 1;40(7):719-728. doi: 10.1200/JCO.21.01455. Epub 2022 Jan 24. J Clin Oncol. 2022. PMID: 35073148 Clinical Trial.
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
Gefard-Gontier E, Markich R, Zysman M, Veillon R, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Lefort F, Prey S, Dutriaux C, Gerard E, Dousset L, Pham-Ledard A, Beylot-Barry M, Schaeverbeke T, Kostine M. Gefard-Gontier E, et al. Among authors: domblides c. Cancer Immunol Immunother. 2022 Nov;71(11):2609-2618. doi: 10.1007/s00262-022-03180-x. Epub 2022 Mar 19. Cancer Immunol Immunother. 2022. PMID: 35305123 Free PMC article.
56 results